Frazier Financial Advisors LLC Sells 388 Shares of Johnson & Johnson (NYSE:JNJ)

Frazier Financial Advisors LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 38.3% during the third quarter, Holdings Channel.com reports. The fund owned 625 shares of the company’s stock after selling 388 shares during the period. Frazier Financial Advisors LLC’s holdings in Johnson & Johnson were worth $101,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson in the first quarter worth about $765,000. Empowered Funds LLC raised its stake in Johnson & Johnson by 46.7% in the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after buying an additional 32,244 shares in the last quarter. Motco raised its stake in Johnson & Johnson by 4.1% in the first quarter. Motco now owns 97,659 shares of the company’s stock worth $15,449,000 after buying an additional 3,846 shares in the last quarter. Sentry Investment Management LLC increased its position in shares of Johnson & Johnson by 9.8% during the first quarter. Sentry Investment Management LLC now owns 13,868 shares of the company’s stock worth $2,194,000 after purchasing an additional 1,241 shares in the last quarter. Finally, J.Safra Asset Management Corp increased its position in shares of Johnson & Johnson by 37.6% during the first quarter. J.Safra Asset Management Corp now owns 1,047 shares of the company’s stock worth $166,000 after purchasing an additional 286 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Trading Up 1.4 %

JNJ stock opened at $154.00 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s 50-day simple moving average is $161.35 and its 200-day simple moving average is $156.10. The firm has a market cap of $370.77 billion, a P/E ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the firm earned $2.66 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.